ScreenerHero

KLRAKailera Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · kailera.com
17.17USD-6.28%Mkt Cap: 2.23B $P/E: —

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pi…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap2.23B $
Enterprise Value1.36B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-148.96M $
Revenue/Share—
Last Price17.17 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees145
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.06
PEG—
EV/EBITDA-4.34
EV/Revenue—
P/S—
P/B2.02
EPS (TTM)-2.15
EPS (Forward)-4.30
52W Range
16.397% of range28.23
52W High28.23 USD
52W Low16.39 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE41.79%
ROA-21.52%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-120.21M $
CapEx (TTM)2.09M $
FCF Margin—
FCF Yield—
Net Debt-906.52M $
Net Debt/EBITDA2.90
Balance Sheet
Debt/Equity-0.03
Current Ratio11.11
Quick Ratio11.03
Book Value/Sh8.629 USD
Cash/Share7.071 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)42.40 USD
Upside (mean)+146.9%
Target Range30.00 USD – 57.00 USD
$30.00+146.9% to mean$57.00
# Analysts5
Ownership
Shares Out.129.64M
Float58.48M
Insiders8.88%
Institutions89.61%
Short Interest
Short Ratio10.9d
Short % Float5.11%
Short % Out.5.11%
Shares Short6.63M
Short (prev mo.)5.10M
Technical
SMA 5019.25 (-10.8%)
SMA 20020.67 (-16.9%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)483.79K
Avg Vol (10d)638.52K
Technical Indicators
RSI (14)40.2
MACD-0.3667
MACD Signal-0.3783
MACD Hist.+0.0115
BB Upper19.35 USD
BB Middle17.89 USD
BB Lower16.44 USD
BB Width16.26%
ATR (14)1.153 USD
Vol Ratio (20d)0.80x